CN101368964A - Chemical luminescence method immune analysis diagnostic reagent kit for detecting cytomegalovirus IgG antibody - Google Patents
Chemical luminescence method immune analysis diagnostic reagent kit for detecting cytomegalovirus IgG antibody Download PDFInfo
- Publication number
- CN101368964A CN101368964A CN 200810105413 CN200810105413A CN101368964A CN 101368964 A CN101368964 A CN 101368964A CN 200810105413 CN200810105413 CN 200810105413 CN 200810105413 A CN200810105413 A CN 200810105413A CN 101368964 A CN101368964 A CN 101368964A
- Authority
- CN
- China
- Prior art keywords
- antibody
- weight
- preparation
- fitc
- cytomegalovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a chemiluminescence immunoassay analysis diagnosing test kit and a preparing method thereof for detecting cytomegalovirus IgG antibody. The test kit includes positive and negative reference substance, solid-phase carrier, labeled antigen, enzyme-labeled antibody, chemiluminescence zymolyte liquid and condensed washing liquid. The test kit has great significance in screening diagnosis and monitoring for pre-pregnancy and early-pregnancy infection of childbearing women as well as CMV infection diagnosis of high risk group (such as tumour, organ transplanting, HIV and the like ).
Description
Technical field
The present invention relates to medical immunology external diagnosis reagent field, more particularly, relate to diagnostic kit of the detection cytomegalovirus IgG antibody that the indirect coating technique of a kind of FITC of employing antibody-FITC combines with chemiluminescence immune assay and preparation method thereof.
Background technology
Cytomegalovirus (Cytomegalovirus.CMV) is a kind of virus that Smith separated from a dead baby's salivary gland in 1956,1964 is cytomegalovirus by definite designation, belonging to herpetoviridae, be double-stranded DNA virus, is a kind of species specificity virus of wide-scale distribution.Cmv infection is worldwide distribution, and the people is unique host of CMV, its popular because of the area and socioeconomic status different.Change of serum C MV antibody positive rate is 50～80% among the adult crowd in North America and Europe, and positive rate of antibody nearly 100% among the crowd in Asia and Africa.
Adult's cmv infection and immunologic function have substantial connection.As the person that accepts the immunosuppressant treatment because of organ transplant, often because of in confession organ and the input blood latent virus being arranged, or immunosupress makes the virus activation of hiding and falls ill, blood transfusion, organ or bone-marrow transplantation can make the danger of former of CMV and scabies secondary infection increase, and are one of major reasons that causes at present organ or bone-marrow transplantation failure.
Cause one of five big pathogen of embryo's deformity as pregnant woman's intrauterine infection, congenital cmv infection can cause patient's congenital abnormality, as feeblemindedness, deafness, choroidoretinitis etc., it is the great research topic in perinatal medicine and the eugenics, bring white elephant for society and family, also seriously influenced the health of newborns of China simultaneously.
When body suffered cmv infection, (immunoglobulin (Ig) was Ig) to resist the invasion of CMV can to produce corresponding antibody in the body.The general IgM antibody that produces earlier produces IgG antibody then.The IgM antibody titer begins to drop to gradually reduced levels after peaking, then basicly stable in a higher titre and lasting long period after IgG antibody peaks.Pregnant method preceding, that pregnancy period detection IgG, IgM combine commonly used is clinically carried out CMV examination or diagnosis.Gestation is early stage anti--CMV IgM or IgG to be occurred and transfers the positive to by feminine gender and be indicated as primary infection, and pregnant only resisting in early days-the CMV IgG positive, occur at second trimester anti--diagnosablely during CMV IgM be secondary infection, only the serum individual event anti--the positive explanation of CMV IgG previous infection.
The etiological diagnosis method of CMV has the meaning of making a definite diagnosis, but has shortcomings such as operation is difficult, sensitivity is low.Thereby serological test is the important auxiliary diagnosis means of present widespread use.Serological diagnostic method commonly used mainly comprises complement fixation test (CFT) (CF), latex agglutination, radiommunoassay (RIA), enzyme-linked immuno assay (EIA) and Western blot (WB) etc.
There is the low shortcoming of susceptibility in complement fixation test (CFT), and the subjectivity of latex agglutination result of determination makes error up to 5% (comprising false negative).Though radiommunoassay is highly sensitive, the height is special, there is term of validity weak point, has alpha-contamination shortcoming.Though the enzyme-linked immuno assay term of validity is long, high specificity, exist substrate most of poisonous or be shortcomings such as carcinogen.WB combines high-resolution gel electrophoresis and highly sensitive immune solid phase technique, consuming timely reaches 16 hours but test.
Chemiluminescence immune assay (Chemiluminescence Immunoassay, CLIA) being worldwide to develop very fast on-radiation immunoassay over past ten years, is a kind of supersensitive microdetermination technology that grows up after radiommunoassay and EIA enzyme immunoassay.Chemiluminescence immune assay combines with the high specific immune response of antibody antigen with high-sensitive chemiluminescence detection technology, have advantages such as wide, easy and simple to handle quick, pollution-free, the instrument simple economy of high sensitivity, sensing range.It is radioimmunoassay and the desirable substituent of normal enzyme immunoassay, is present optimal immune analysis method.
The chemiluminescence immune assay principle that adopts enzymatic to strengthen is encrusting substance specificity on determinand, enzyme labeling thing and the solid phase carrier in the sample in conjunction with the antigen-antibody complex that forms enzyme labeling, the catalytic luminescence substrate reactions, the free energy that utilizes chemical reaction to discharge excites intermediate luminous, thus determinand in the test sample.
Fluorescein isothiocynate (FITC) is a kind of very stable fluorescence element, very easily is combined on the protein molecular, and not only mark is simple, and label is very stable.FITC is attached to as haptens has very strong immunogenicity on the protein carrier, FITC monoclonal antibody and the FITC reaction that is marked on the protein, and not only specificity height, and affinity also is higher than the combination of antigen-antibody.The present invention is with FITC antibody sandwich solid phase carrier, wrap indirectly by the antibody of FITCization by FITC antibody-FITC system, not only be convenient to amplify and produce, be easy to monitoring industrial processes, and shortcoming such as the loss of activity of having avoided the direct coated solid phase to exist is big, process optimization is loaded down with trivial details, the stability between having guaranteed simultaneously batch.
Summary of the invention
For solve at present clinically aetology test operation inconvenience, sensitivity is low, put that the agent term of validity of being excused from an examination is short, radioactive waste contamination hazard and enzyme are excused from an examination that agent is subjected to that multiple factor is disturbed, the most of deficiency such as poisonous of substrate, the invention provides a kind of chemical luminescence immune analysis diagnosis reagent kit that detects cytomegalovirus IgG antibody.Kit of the present invention is by negative, positive control, solid phase carrier, labelled antigen, enzyme labelled antibody, chemical luminous substrate liquid, and concentrated cleaning solution is formed, wherein, described solid phase carrier is for wrapping by the microwell plate of FITC antibody or magnetic-particle, and labelled antigen is the cytomegalovirus antigen of FITC mark, and enzyme labelled antibody is the Anti-Human IgG monoclonal antibody of alkali phosphatase enzyme mark.
Use kit of the present invention to detect cytomegalovirus IgG antibody, have easy and simple to handle, highly sensitive, specificity is good, with advantages such as aetology assay degree of conformity is high.
The present invention also provides a kind of preparation method who detects the chemical luminescence immune analysis diagnosis reagent kit of cytomegalovirus IgG antibody, may further comprise the steps:
A, bag are by the preparation of solid phase carrier: with containing the 50mmol/L pH9.6 carbonate buffer solution solution bag of 0.1～6 μ g/mL FITC antibody by solid phase carrier, 2～8 ℃ of bags are by after 18～20 hours, with the 20mmol/L pH7.4 Tris-HCl damping fluid sealing that contains 0.2%Casein (weight) 18～20 hours, abandon dehumidifier behind the most confining liquid, drying, the aluminium foil bag sealing.
The preparation of B, FITC mark cytomegalovirus antigen: will add the FITC of DMSO dissolving with the cytomegalovirus antigen of 50mmol/L pH9.6 carbonic acid buffer dialysis, purifying, packing, low-temperature dark are preserved behind the reaction terminating.Adopt the chessboard titrimetry to select best FITC labelled antigen working concentration, and be dissolved in 0.2%Casein (weight), in the 20mmol/L pH7.4 Tris-HCl damping fluid with the cytomegalovirus antigen working solution of preparation FITC mark.
The preparation of C, alkali phosphatase enzyme mark Anti-Human IgG monoclonal anti liquid solution: adopt glutaraldehyde method to prepare alkali phosphatase enzyme mark Anti-Human IgG monoclonal antibody, adopt the chessboard titrimetry to select best enzyme labelled antibody working concentration, and be dissolved in 0.2%Casein (weight), in the 20mmol/L pH7.4 Tris-HCl damping fluid with preparation enzyme labelled antibody working solution.
The preparation of D, luminous substrate liquid:
Chemical luminous substrate liquid contains:
AMPPD 10～30% (volume)
NaCl 12～20% (weight)
KCl 0.1～0.7% (weight)
Tris-HCl damping fluid 50～500mmol/L pH8.0～10.0.
On the basis of technique scheme, preferred described chemical luminous substrate liquid contains:
AMPPD 20% (volume)
NaCl 16% (weight)
KCl 0.4% (weight)
Tris-HCl damping fluid 200mmol/L pH8.0～10.0.
The preparation of E, concentrated cleaning solution:
Concentrated cleaning solution contains:
NaCl 12～20% (weight)
KCl 0.1～0.7% (weight)
Polysorbas20 0.05～0.2% (volume)
Tris-HCl damping fluid 50～500mol/L pH7.2～7.6
Use 20 times of dilutions of distilled water during use.
On the basis of technique scheme, preferred described concentrated cleaning solution contains:
NaCl 16% (weight)
KCl 0.4% (weight)
Polysorbas20 0.1% (volume)
Tris-HCl damping fluid 200mmol/L pH7.4
Use 20 times of dilutions of distilled water during use.
The preparation of F, feminine gender, positive reference substance
Collection detects the negative normal human serum of cytomegalovirus IgG antibody, HBsAg, HIV (1+2) antibody, TP antibody, HCV antibody more than 6 parts through the ELISA method, filtration sterilization, packing, low-temperature storage.
Collection detects the cytomegalovirus IgG antibody positive through the ELISA method, and the negative patients serum of HBsAg, HIV (1+2) antibody, TP antibody, HCV antibody is more than 6 parts, appropriateness dilution back filtration sterilization, packing, low-temperature storage.
This method is convenient to produce, be easy to monitoring industrial processes, the stability between having guaranteed batch.
Embodiment
Following institute gives an actual example and only is used to explain the present invention, is not to be used to limit scope of the present invention.
Embodiment 1
A kind of preparation that detects the chemical luminescence immune analysis diagnosis reagent kit of cytomegalovirus IgG antibody:
A, bag are prepared by plate:
With the 50mmol/L pH9.6 carbonate buffer solution solution that contains 2.5 μ g/ml FITC antibody, with 100 μ L/ pore volume bags by microwell plate, 2～8 ℃ of bags are by after 18～20 hours, with the 20mmol/L pH7.4 Tris-HCl damping fluid 180 μ L/ holes sealing that contains 0.2%Casein (weight) 18～20 hours, get rid of dehumidifier behind the most confining liquid, 28 ℃ of dryings 18～20 hours add the drying agent sealing, place 2～8 ℃ of preservations.
The preparation of B, FITC mark cytomegalovirus antigen:
A), FITC labeling method: with cytomegalovirus antigen 1 mg 50mmol/L pH9.6 carbonic acid buffer dialysed overnight under 2～8 ℃ of conditions, in cytomegalovirus antigen: the ratio of FITC=1mg:200 μ g slowly adds 1mg/mL FITC (dimethyl sulfoxide (DMSO) is a solvent) solution in the cytomegalovirus antigenic solution and mixes, 2～8 ℃ of reactions of lucifuge 4 hours, the NH of adding 5mol/L
4Cl solution is to final concentration 50mmol/L, 2～8 ℃ of cessation reactions 2 hours, in 20mmol/L pH7.4 Tris-HCl damping fluid, dialyse the cytomegalovirus antigenic solution of FITC mark limpid to dislysate, add in the 20mmol/L Tris-HCl damping fluid of 0.1% (volume) Proclin 300,1% (weight) bovine serum albumin(BSA) (BSA) pH7.4, preserve 2～8 ℃ of dark places.
B), the preparation of FITC labelled antigen dilution
2.42g Tris and 2g Casein adding are dissolved in the 900ml distilled water, adjust pH to 7.4 with HCl, fixed molten with distilled water to 1000mL.
C), the preparation of FITC labelled antigen working fluid
The FITC labelled antigen of preparation is diluted to variable concentrations respectively with dilution, uses the chessboard titrimetry to select best dilutability and be 1:6000.
C, alkali phosphatase enzyme mark Anti-Human IgG MONOCLONAL ANTIBODIES SPECIFIC FOR:
A), labeling method: adopt glutaraldehyde method with alkaline phosphatase and the coupling of Anti-Human IgG monoclonal antibody, add 50% glycerine, place-20 ℃ frozen.
B), the preparation of enzyme labeling thing dilution
2.42g Tris and 2g Casein adding are dissolved in the 900ml distilled water, adjust pH to 7.4 with HCl, fixed molten with distilled water to 1000mL.
C), the preparation of enzyme labeling thing working fluid
The enzyme labeling thing of preparation is diluted to variable concentrations respectively with dilution, uses the chessboard titrimetry to select best dilutability and be 1:10000.
The preparation of D, luminous substrate liquid:
200ml AMPPD, 160g NaCl, 4g KCl, 24.2g trishydroxymethylaminomethane (Tris) are dissolved in the 900ml distilled water, adjust pH8.0～10.0 with HCl, fixed molten with distilled water to 1000mL.
The preparation of E, concentrated cleaning solution:
160g NaCl, 4g KCl, 24.2g trishydroxymethylaminomethane (Tris), 1ml polysorbas20 are dissolved in the 900ml distilled water, are adjusted to pH7.4 with HCl, fixed molten with distilled water to 1000mL.
Use 20 times of dilutions of distilled water during use.
The preparation of F, feminine gender, positive reference substance:
The normal human serum that collection detects cytomegalovirus IgG antibody, HBsAg, HIV (1+2) antibody, TP antibody, HCV negative antibody through the ELISA method is more than 6 parts, filtration sterilization, packing, low-temperature storage.
Collection detects the cytomegalovirus IgG antibody positive through the ELISA method, and the patients serum of HBsAg, HIV (1+2) antibody, TP antibody, HCV negative antibody suitably dilutes back filtration sterilization, packing, low-temperature storage more than 6 parts.
Embodiment 2
A kind of preparation that detects the chemical luminescence immune analysis diagnosis reagent kit of cytomegalovirus IgG antibody:
With magnetic-particle as solid phase carrier, adopt the EDC method with FITC antibody covalent coupling to the magnetic-particle surface, and be concentrated cleaning solution with the 50mmol/L pH7.2Tris-HCl damping fluid that contains 12% (weight) NaCl, 0.1% (weight) KCl, all the other all prepare the chemical luminescence immune analysis diagnosis reagent kit of present embodiment cytomegalovirus IgG antibody with the method identical with embodiment 1.
Embodiment 3
A kind of preparation that detects the chemical luminescence immune analysis diagnosis reagent kit of cytomegalovirus IgG antibody:
(1), the preparation of luminous substrate liquid:
100ml AMPPD, 120g NaCl, 1g KCl, 6.05g trishydroxymethylaminomethane (Tris) are dissolved in the 900ml distilled water, adjust pH8.0～10.0 with HCl, fixed molten with distilled water to 1000mL.
(2), the preparation of concentrated cleaning solution:
120g NaCl, 1g KCl, 6.05g trishydroxymethylaminomethane (Tris), 0.5ml polysorbas20 are dissolved in the 900ml distilled water, are adjusted to pH7.2 with HCl, fixed molten with distilled water to 1000mL.
Use 20 times of dilutions of distilled water during use.
All the other preparation methods are with embodiment 1.
Embodiment 4
A kind of preparation that detects the chemical luminescence immune analysis diagnosis reagent kit of cytomegalovirus IgG antibody:
(1), the preparation of luminous substrate liquid:
With 300ml AMPPD, 200g NaCl, 7g KCl, 60.5g trishydroxymethylaminomethane (Tris), be dissolved in the 900ml distilled water, adjust pH8.0～10.0 with HCl, fixed molten with distilled water to 1000mL.
(2), the preparation of concentrated cleaning solution:
200g NaCl, 7g KCl, 60.5g trishydroxymethylaminomethane (Tris), 2ml polysorbas20 are dissolved in the 900ml distilled water, adjust pH to 7.6 with HCl, fixed molten with distilled water to 1000mL.
Use 20 times of dilutions of distilled water during use.
All the other preparation methods are with embodiment 1.
Embodiment 5
A kind of using method that detects the chemical luminescence immune analysis diagnosis reagent kit of cytomegalovirus IgG antibody.
(1) takes out prepared cytomegalovirus IgG antibody chemical luminescence method immune analysis diagnostic reagent kit among the embodiment 1, equilibrium at room temperature 15-30 minute.
(2), sample to be tested is diluted by 1:100 in advance with physiological saline.
(3), added feminine gender, positive control and pre-diluted sample 50 μ L respectively by plate, every then hole adds 50 μ L FITC labelled antigens respectively, vibration mixing, 37 ℃ of incubations 30 minutes at bag.
(4), with the dilution after cleansing solution wash 5 times, cleansing solution is filled it up with in every hole, soaks 10 seconds at every turn, pats dry on clean thieving paper at last.
(5), each hole adds enzyme labelled antibody 100 μ L, vibration mixing, 37 ℃ of incubations 30 minutes.
(6), repeating step (4).
(7), each hole adds chemical luminous substrate liquid 100 μ L, room temperature (20～25 ℃) lucifuge reaction 30 minutes.
(8), add in the 30th～60 minute behind the chemical luminous substrate liquid and measure, on the chemiluminescence measuring instrument, measure the luminous intensity (RLU) in each hole in regular turn, 1 second/hole of Measuring Time; Cutoff value=2.1NC, RLU value 〉=Cutoff value then sample is judged to be positive sample; RLU value＜Cutoff value then sample is judged to be negative sample.
Embodiment 6
A kind of using method that detects the chemical luminescence immune analysis diagnosis reagent kit of cytomegalovirus IgG antibody.
(1), with cytomegalovirus IgG antibody chemical luminescence method immune analysis diagnostic reagent kit equilibrium at room temperature prepared among the embodiment 2 15-30 minute.
(2), sample to be tested is diluted by 1:100 in advance with physiological saline.
(3), negative, positive control and sample to be tested 50 μ L are added the round bottom polystyrene test tube of numbering respectively, every then pipe adds FITC labelled antigen 50 μ L, magnetic-particle 100 μ L respectively, 37 ℃ of oscillating reactionss 15 minutes.
(4), test tube rack placed separates 1min on the magnetic separator, the separation vessel that reverses is then poured out supernatant, the test tube of reversing is placed on the filter paper blots, and bounces separation vessel to remove wall built-up liquid.Every pipe adds cleansing solution 500 μ L, and fully mixing places and separates 1min on the magnetic separator, pours out supernatant, the test tube that reverses is placed on the filter paper blots, and bounces separation vessel to remove wall built-up liquid, repeats 4 times.
(5), each pipe adds enzyme labelled antibody 100 μ L, 37 ℃ of oscillating reactionss 15 minutes.
(6), repeating step (4).
(7), each pipe adds chemical luminous substrate liquid 200～400 μ L, fully mixing places in the magnetic separator, treat that magnetic particle is enriched in the bottom after, luminous intensity (RLU) is measured after placing 30min in regular turn in the dark place on the chemiluminescence measuring instrument, 1 second/pipe of Measuring Time; Cutoff value=2.1NC, RLU value 〉=Cutoff value then sample is judged to be positive sample; RLU value＜Cutoff value then sample is judged to be negative sample.
Embodiment 7
Adopt cytomegalovirus IgG antibody chemical luminescence immune analysis diagnosis reagent kit prepared among the embodiment 1 that 30 routine normal person's blood samples and cytomegalovirus previous infection sample 74 examples of making a definite diagnosis are detected, trace routine and result's judgement are carried out in strict accordance with the using method that embodiment 5 provides.
The result is as follows:
Table 1 kit clinical testing of the present invention evaluation result
The described data of table 1 show, kit specificity of the present invention, susceptibility are all good, and kit positive predictive value of the present invention, negative predictive value are 100%.
The above only is preferred embodiment of the present invention, and is in order to restriction the present invention, within the spirit and principles in the present invention not all, any modification of being done, is equal to replacement, improvement etc., all should be included within protection scope of the present invention.
Claims (7)
1. chemical luminescence immune analysis diagnosis reagent kit that detects cytomegalovirus IgG antibody, it is characterized in that described kit is made up of by Anti-Human IgG monoclonal antibody, chemical luminous substrate and the concentrated cleaning solution of the cytomegalovirus antigen of the solid phase carrier of FITC antibody, FITC mark, alkali phosphatase enzyme mark feminine gender, positive control, bag.
2. kit according to claim 1 is characterized in that, described solid phase carrier is microwell plate or magnetic-particle.
3. kit according to claim 1, it is characterized in that described chemical luminous substrate liquid consists of: 50～500mmol/L Tris-HCl buffer solution of 10～30% (volume) AMPPD, 12～20% (weight) NaCl, 0.1～0.7% (weight) KCl, pH8.0～10.0.
4. kit according to claim 1 is characterized in that, described chemical luminous substrate liquid consists of: 20% (volume) AMPPD, the 200mmol/L Tris-HCl damping fluid of 16% (weight) NaCl, 0.4% (weight) KCl, pH 8.0～10.0.
5. method for preparing the described kit of claim 1 is characterized in that may further comprise the steps:
A, bag are by the preparation of solid phase carrier: with containing the 50mmol/L pH9.6 carbonate buffer solution solution bag of 0.1～6 μ g/mL FITC antibody by solid phase carrier, 2～8 ℃ of bags are by after 18～20 hours, with the 20mmol/L pH7.4Tris-HCl damping fluid sealing that contains 0.2%Casein (weight) 18～20 hours, abandon dehumidifier behind the most confining liquid, drying, the aluminium foil bag sealing.
The preparation of B, FITC mark cytomegalovirus antigen: will add the FITC of DMSO dissolving with the cytomegalovirus antigen of 50mmol/L pH 9.6 carbonic acid buffers dialysis, purifying, packing, low-temperature dark are preserved behind the reaction terminating.Adopt the chessboard titrimetry to select best FITC labelled antigen working concentration, and be dissolved in 0.2%Casein (weight), in the 20mmol/L pH7.4Tris-HCl damping fluid with the cytomegalovirus antigen working solution of preparation FITC mark.
The preparation of C, alkali phosphatase enzyme mark Anti-Human IgG monoclonal anti liquid solution: adopt glutaraldehyde method to prepare alkali phosphatase enzyme mark Anti-Human IgG monoclonal antibody, adopt the chessboard titrimetry to select best enzyme labelled antibody working concentration, and be dissolved in 0.2%Casein (weight), in the 20mmol/L pH7.4Tris-HCl damping fluid with preparation enzyme labelled antibody working solution.
The preparation of D, luminous substrate liquid:
Chemical luminous substrate liquid contains:
AMPPD 10～30% (volume)
NaCl 12～20% (weight)
KCl 0.1～0.7% (weight)
Tris-HCl damping fluid 50～500mmol/L
pH 8.0～10.0。
The preparation of E, concentrated cleaning solution:
Concentrated cleaning solution contains:
NaCl 12～20% (weight)
KCl 0.1～0.7% (weight)
Polysorbas20 0.05～0.2% (volume)
Tris-HCl damping fluid 50～500mol/L
pH 7.2～7.6
Use 20 times of dilutions of distilled water during use.
The preparation of F, feminine gender, positive control
Collection detects the negative normal human serum of cytomegalovirus IgG antibody, HBsAg, HIV (1+2) antibody, TP antibody, HCV antibody more than 6 parts through the ELISA method, filtration sterilization, packing, low-temperature storage.
Collection detects the cytomegalovirus IgG antibody positive through the ELISA method, and the negative patients serum of HBsAg, HIV (1+2) antibody, TP antibody, HCV antibody is more than 6 parts, suitably dilution back filtration sterilization, packing, low-temperature storage.
6. the preparation method of chemical luminescence immune analysis diagnosis reagent kit according to claim 5 is characterized in that, described chemical luminous substrate liquid contains:
AMPPD 20% (volume)
NaCl 16% (weight)
KCl 0.4% (weight)
Tris-HCl damping fluid 200mmol/L
pH 8.0～10.0。
7. the preparation method of chemical luminescence immune analysis diagnosis reagent kit according to claim 5 is characterized in that, described concentrated cleaning solution contains:
NaCl 16% (weight)
KCl 0.4% (weight)
Polysorbas20 0.1% (volume)
Tris-HCl damping fluid 200mmol/L
pH 7.4
Use 20 times of dilutions of distilled water during use.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200810105413 CN101368964A (en) | 2008-04-29 | 2008-04-29 | Chemical luminescence method immune analysis diagnostic reagent kit for detecting cytomegalovirus IgG antibody |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200810105413 CN101368964A (en) | 2008-04-29 | 2008-04-29 | Chemical luminescence method immune analysis diagnostic reagent kit for detecting cytomegalovirus IgG antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101368964A true CN101368964A (en) | 2009-02-18 |
Family
ID=40412879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200810105413 Pending CN101368964A (en) | 2008-04-29 | 2008-04-29 | Chemical luminescence method immune analysis diagnostic reagent kit for detecting cytomegalovirus IgG antibody |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101368964A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102353777A (en) * | 2011-07-05 | 2012-02-15 | 深圳市卫武光明生物制品有限公司 | Kit and method for testing human cytomegalovirus IgG antibody |
| CN102565032A (en) * | 2010-12-15 | 2012-07-11 | 北京勤邦生物技术有限公司 | Magnetic granule chemiluminescence kit for detecting nitrofurantoin metabolite and application of magnetic granule chemiluminescence kit |
| CN103197077A (en) * | 2013-03-20 | 2013-07-10 | 郑州伊美诺生物技术有限公司 | Assay kit for detecting trace bovine immunoglobulin G |
| CN109342718A (en) * | 2018-09-29 | 2019-02-15 | 宁波奥丞生物科技有限公司 | A kind of magnetic microparticle chemiluminescence detection method |
| CN113189348A (en) * | 2021-06-08 | 2021-07-30 | 中山生物工程有限公司 | Hepatitis C virus antibody detection kit and application thereof |
-
2008
- 2008-04-29 CN CN 200810105413 patent/CN101368964A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102565032A (en) * | 2010-12-15 | 2012-07-11 | 北京勤邦生物技术有限公司 | Magnetic granule chemiluminescence kit for detecting nitrofurantoin metabolite and application of magnetic granule chemiluminescence kit |
| CN102353777A (en) * | 2011-07-05 | 2012-02-15 | 深圳市卫武光明生物制品有限公司 | Kit and method for testing human cytomegalovirus IgG antibody |
| CN103197077A (en) * | 2013-03-20 | 2013-07-10 | 郑州伊美诺生物技术有限公司 | Assay kit for detecting trace bovine immunoglobulin G |
| CN109342718A (en) * | 2018-09-29 | 2019-02-15 | 宁波奥丞生物科技有限公司 | A kind of magnetic microparticle chemiluminescence detection method |
| CN113189348A (en) * | 2021-06-08 | 2021-07-30 | 中山生物工程有限公司 | Hepatitis C virus antibody detection kit and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Parry et al. | Diagnosis of hepatitis A and B by testing saliva | |
| Bradley et al. | Serodiagnosis of viral hepatitis A by a modified competitive binding radioimmunoassay for immunoglobulin M anti-hepatitis A virus | |
| CN101373189A (en) | Chemical luminescence immune analysis diagnosis reagent kit detecting Toxoplasma Gondi IgG antibody and preparation method thereof | |
| CN101738473B (en) | Treponema pallidum antibody diagnostic kit and preparation method thereof | |
| CN103235120B (en) | Kit for compound detection of hepatitis E virus antibody profile as well as application of kit | |
| CN101377504A (en) | Chemiluminescence immune analysis determination reagent kit for detecting Toxoplasma Gondi IgM antibody | |
| CN109100516A (en) | A kind of detection cytomegalovirus IgG antibody chemical luminescence immune assay determination reagent kit and preparation method thereof | |
| CN101368964A (en) | Chemical luminescence method immune analysis diagnostic reagent kit for detecting cytomegalovirus IgG antibody | |
| CN101368965A (en) | Chemical luminescence method immune analysis diagnostic reagent kit for detecting cytomegalovirus IgM antibody | |
| MX2010012363A (en) | Point of care test for the detection of exposure or immunity to dengue virus. | |
| CN102368068B (en) | Kit for detecting chlamydia pneumoniae IgM antibody | |
| EP0038150A1 (en) | Sero-diagnostic method for syphilis and other diseases | |
| US20080206790A1 (en) | Assay for determining the presence or amount of newly synthesized antibodies | |
| CN1580772A (en) | SARS virus antibody double antigen sandwich ELISA detecting method | |
| JPH03502248A (en) | Aqueous washing solution for assay, diagnostic test kit and method for measuring herpes simplex virus | |
| CN101581720A (en) | Kit for confirming human immunodeficiency virus antibody | |
| CN101551395A (en) | Chemiluminescence immunoassay kit of hepatitis E virus IgM antibody and preparation method thereof | |
| WO1992009895A1 (en) | Composition and its preparation process using antigen conjugated to enzymatic activity for immunological diagnosis and chagas' disease immunological diagnosis kits, for individual and epidemiological application, based on that composition | |
| CN101551396A (en) | Chemiluminscence immunoassay kit of hepatitis E virus IgG antibody and preparation method thereof | |
| CN101533025A (en) | Chemoluminescent immunoassay kit of hepatitis A virus IgM antibody and preparation method thereof | |
| CN101368960A (en) | Chemical luminescence immune assay determination reagent kit for rubella virus IgM antibody and preparation method thereof | |
| CN104049088A (en) | Chemiluminescent quantitative detection kit for blood plasma HSP70 (heat shock protein) antibody | |
| CN101377494B (en) | Chemiluminescence immune analytic reagent kit for detecting tuberculosis antibody | |
| CN101368959A (en) | Chemical luminescence immune assay determination reagent kit for rubella virus IgG antibody and preparation method thereof | |
| CN103149356B (en) | A kind of Test paper card utilizing sandwich method to detect Brucella abortus antigen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIJING KEMEI BIOLOGICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: KEMEI DONGYA BIOLOGICAL TECHNOLOGY CO., LTD., BEIJING Effective date: 20111028 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20111028 Address after: 100094 Beijing city Haidian District Yongfeng base Feng Xian Road No. 7 North Park Applicant after: Beijing Kemei Biological Technology Co., Ltd. Address before: 100094 Beijing city Haidian District Yongfeng base Feng Xian Road No. 7 North Park Applicant before: Kemei Dongya Biological Technology Co., Ltd., Beijing |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20090218 |